Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Schuler

Showing results (221-230 of 298) with videos related to

Pageof 30
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 28, 2023
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancerPeter A Fasching, Thomas Decker, Andreas Hartkopf, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2020
Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression contextMarcel Wiesweg, Fabian Mairinger, Henning Reis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.
Breast Cancer Research and Treatment|July 6, 2012
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerMartin Schuler, Ahmad Awada, Philipp Harter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 24, 2025
<sup>90</sup>Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous TumorsHelena Lanzafame, Christoph E Heilig, Eva Wardelmann, et al.
Clinical Lung Cancer|April 11, 2018
MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and ImmunotherapyHenning Reis, Martin Metzenmacher, Moritz Goetz, et al.
Therapeutic Advances in Medical Oncology|June 9, 2021
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancerMartin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2026
<SPAN style="font-weight: 400;">Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer</SPAN>Julius Keyl, René Hosch, Fabian Hörst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I studyAnjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2023
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> MutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.
Pageof 30

Showing results (221-230 of 298) with videos related to

Sort By:
Pageof 30
European Journal of Cancer (Oxford, England : 1990)|December 28, 2023
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancerPeter A Fasching, Thomas Decker, Andreas Hartkopf, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2020
Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression contextMarcel Wiesweg, Fabian Mairinger, Henning Reis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.
Breast Cancer Research and Treatment|July 6, 2012
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerMartin Schuler, Ahmad Awada, Philipp Harter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 24, 2025
<sup>90</sup>Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous TumorsHelena Lanzafame, Christoph E Heilig, Eva Wardelmann, et al.
Clinical Lung Cancer|April 11, 2018
MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and ImmunotherapyHenning Reis, Martin Metzenmacher, Moritz Goetz, et al.
Therapeutic Advances in Medical Oncology|June 9, 2021
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancerMartin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2026
<SPAN style="font-weight: 400;">Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer</SPAN>Julius Keyl, René Hosch, Fabian Hörst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I studyAnjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2023
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> MutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.
Pageof 30